Kratom Revisions

25
4-45-104
58-37-2
58-37-4
0
Kratom Revisions
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Evan J. Vickers
House Sponsor: Jake Sawyer
LONG TITLE
Committee Note:
The Business and Labor Interim Committee recommended this bill.
Legislative Vote:
16 voting for
0 voting against
4 absent
General Description:
This bill amends provisions related to kratom.
Highlighted Provisions:
This bill:
defines terms;
schedules 7-hydroxymitragynine, including synthetics, if the 7-hydroxymitragynine
concentration exceeds a certain percentage as a schedule I controlled substance; and
schedules Mitragynine pseudoindoxyl, including synthetics.
Money Appropriated in this Bill:
None
Other Special Clauses:
This bill provides a special effective date.
Utah Code Sections Affected:
AMENDS:
4-45-104
, as enacted by Laws of Utah 2019, Chapter 329
58-37-2
, as last amended by Laws of Utah 2025, Chapter 396
58-37-4
, as last amended by Laws of Utah 2025, Chapter 216
Be it enacted by the Legislature of the state of Utah:
Section 1. Section
4-45-104
is amended to read:
4-45-104
. Kratom processor requirements -- Criminal penalty.
(1)
A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product:
(a)
that is mixed or packed with a nonkratom substance that affects the quality or
strength of the kratom product to such a degree as to render the kratom product
injurious to a consumer;
(b)
that contains a poisonous or otherwise deleterious nonkratom ingredient, including a
controlled substance as defined in Section
58-37-2
;
(c)
containing a level of 7-hydroxymitragynine in the alkaloid fraction that is greater
than 2% of the alkaloid composition of the kratom product
that would be considered
a controlled substance under Section
58-37-4
;
(d)
containing a synthetic alkaloid, including synthetic mitragynine, synthetic
7-hydroxymitragynine, or any other synthetically derived compound of the kratom
plant; or
(e)
that does not include a product label on the kratom product packaging that states the
amount of mitragynine and 7-hydroxymitragynine contained in the packaged kratom
product.
(2)
A kratom processor who violates Subsection
(1)
is guilty of a class C misdemeanor for
each violation.
(3)
A kratom processor does not violate Subsection
(1)
if the kratom processor shows by a
preponderance of the evidence that the kratom processor relied in good faith upon the
representation of a manufacturer, processor, packer, or distributor of food represented to
be a kratom product.
(4)
A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product
that is not registered with the department in accordance with this chapter.
(5)
A kratom processor shall register as a food establishment in accordance with Section
4-5-301
.
Section 2. Section
58-37-2
is amended to read:
58-37-2
. Definitions.
(1)
As used in this chapter:
(a)
"Administer" means the direct application of a controlled substance, whether by
injection, inhalation, ingestion, or any other means, to the body of a patient or
research subject by:
(i)
a practitioner or, in the practitioner's presence, by the practitioner's authorized
agent; or
(ii)
the patient or research subject at the direction and in the presence of the
practitioner.
(b)
"Agent" means an authorized person who acts on behalf of or at the direction of a
manufacturer, distributor, or practitioner but does not include a motor carrier, public
warehouseman, or employee of any of them.
(c)
"Consumption" means ingesting or having any measurable amount of a controlled
substance in a person's body, but this Subsection
(1)(c)
does not include the
metabolite of a controlled substance.
(d)
"Continuing criminal enterprise" means any individual, sole proprietorship,
partnership, corporation, business trust, association, or other legal entity, and any
union or groups of individuals associated in fact although not a legal entity, and
includes illicit as well as licit entities created or maintained for the purpose of
engaging in conduct which constitutes the commission of episodes of activity made
unlawful by this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b,
Imitation Controlled Substances Act, Chapter 37c, Utah Controlled Substance
Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, which episodes are not
isolated, but have the same or similar purposes, results, participants, victims, methods
of commission, or otherwise are interrelated by distinguishing characteristics. Taken
together, the episodes shall demonstrate continuing unlawful conduct and be related
either to each other or to the enterprise.
(e)
"Control" means to add, remove, or change the placement of a drug, substance, or
immediate precursor under Section
58-37-3
.
(f)
(i)
"Controlled substance" means a drug or substance:
(A)
included in Schedules I, II, III, IV, or V of Section
58-37-4
;
(B)
included in Schedules I, II, III, IV, or V of the federal Controlled Substances
Act, Title II, P.L. 91-513;
(C)
that is a controlled substance analog; or
(D)
listed in Section
58-37-4.2
.
(ii)
"Controlled substance" does not include:
(A)
distilled spirits, wine, or malt beverages, as those terms are defined in Title
32B, Alcoholic Beverage Control Act;
(B)
any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,
or prevention of disease in human or other animals, which contains ephedrine,
pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is
lawfully purchased, sold, transferred, or furnished as an over-the-counter
medication without prescription; or
(C)
dietary supplements, vitamins, minerals, herbs, or other similar substances
including concentrates or extracts, which:
(I)
are not otherwise regulated by law; and
(II)
may contain naturally occurring amounts of chemical or substances listed
in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah
Administrative Rulemaking Act.
(g)
(i)
"Controlled substance analog" means:
(A)
a substance the chemical structure of which is substantially similar to the
chemical structure of a controlled substance listed in Schedules I and II of
Section
58-37-4
, a substance listed in Section
58-37-4.2
, or in Schedules I and
II of the federal Controlled Substances Act, Title II, P.L. 91-513;
(B)
a substance that has a stimulant, depressant, or hallucinogenic effect on the
central nervous system substantially similar to the stimulant, depressant, or
hallucinogenic effect on the central nervous system of controlled substances
listed in Schedules I and II of Section
58-37-4
, substances listed in Section
58-37-4.2
, or substances listed in Schedules I and II of the federal Controlled
Substances Act, Title II, P.L. 91-513; or
(C)
A substance that, with respect to a particular individual, is represented or
intended to have a stimulant, depressant, or hallucinogenic effect on the central
nervous system substantially similar to the stimulant, depressant, or
hallucinogenic effect on the central nervous system of controlled substances
listed in Schedules I and II of Section
58-37-4
, substances listed in Section
58-37-4.2
, or substances listed in Schedules I and II of the federal Controlled
Substances Act, Title II, P.L. 91-513.
(ii)
"Controlled substance analog" does not include:
(A)
a controlled substance currently scheduled in Schedules I through V of
Section
58-37-4
;
(B)
a substance for which there is an approved new drug application;
(C)
a substance with respect to which an exemption is in effect for investigational
use by a particular person under Section 505 of the Food, Drug, and Cosmetic
Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is
permitted by the exemption;
(D)
any substance to the extent not intended for human consumption before an
exemption takes effect with respect to the substance;
(E)
any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,
or prevention of disease in man or other animals, which contains ephedrine,
pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is
lawfully purchased, sold, transferred, or furnished as an over-the-counter
medication without prescription; or
(F)
dietary supplements, vitamins, minerals, herbs, or other similar substances
including concentrates or extracts, which are not otherwise regulated by law,
which may contain naturally occurring amounts of chemical or substances
listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah
Administrative Rulemaking Act.
(h)
(i)
"Conviction" means a determination of guilt by verdict, whether jury or bench,
or plea, whether guilty or no contest, for any offense proscribed by:
(A)
this chapter;
(B)
Chapter 37a, Utah Drug Paraphernalia Act;
(C)
Chapter 37b, Imitation Controlled Substances Act;
(D)
Chapter 37c, Utah Controlled Substance Precursor Act; or
(E)
Chapter 37d, Clandestine Drug Lab Act; or
(ii)
for any offense under the laws of the United States and any other state which, if
committed in this state, would be an offense under:
(A)
this chapter;
(B)
Chapter 37a, Utah Drug Paraphernalia Act;
(C)
Chapter 37b, Imitation Controlled Substances Act;
(D)
Chapter 37c, Utah Controlled Substance Precursor Act; or
(E)
Chapter 37d, Clandestine Drug Lab Act.
(i)
"Counterfeit substance" means:
(i)
any controlled substance or container or labeling of any controlled substance that:
(A)
without authorization bears the trademark, trade name, or other identifying
mark, imprint, number, device, or any likeness of them, of a manufacturer,
distributor, or dispenser other than the person or persons who in fact
manufactured, distributed, or dispensed the substance which falsely purports to
be a controlled substance distributed by any other manufacturer, distributor, or
dispenser; and
(B)
a reasonable person would believe to be a controlled substance distributed by
an authorized manufacturer, distributor, or dispenser based on the appearance
of the substance as described under Subsection
(1)(i)(i)(A)
or the appearance of
the container of that controlled substance; or
(ii)
any substance other than under Subsection
(1)(i)(i)
that:
(A)
is falsely represented to be any legally or illegally manufactured controlled
substance; and
(B)
a reasonable person would believe to be a legal or illegal controlled substance.
(j)
"Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
controlled substance or a listed chemical, whether or not an agency relationship exists.
(k)
"Department" means the Department of Commerce.
(l)
"Depressant or stimulant substance" means:
(i)
a drug which contains any quantity of barbituric acid or any of the salts of
barbituric acid;
(ii)
a drug which contains any quantity of:
(A)
amphetamine or any of its optical isomers;
(B)
any salt of amphetamine or any salt of an optical isomer of amphetamine; or
(C)
any substance which the Secretary of Health and Human Services or the
Attorney General of the United States after investigation has found and by
regulation designated habit-forming because of its stimulant effect on the
central nervous system;
(iii)
lysergic acid diethylamide; or
(iv)
any drug which contains any quantity of a substance which the Secretary of
Health and Human Services or the Attorney General of the United States after
investigation has found to have, and by regulation designated as having, a
potential for abuse because of its depressant or stimulant effect on the central
nervous system or its hallucinogenic effect.
(m)
"Dispense" means the delivery of a controlled substance by a pharmacist to an
ultimate user pursuant to the lawful order or prescription of a practitioner, and
includes distributing to, leaving with, giving away, or disposing of that substance as
well as the packaging, labeling, or compounding necessary to prepare the substance
for delivery.
(n)
"Dispenser" means a pharmacist who dispenses a controlled substance.
(o)
"Distribute" means to deliver other than by administering or dispensing a controlled
substance or a listed chemical.
(p)
"Distributor" means a person who distributes controlled substances.
(q)
"Division" means the Division of Professional Licensing created in Section
58-1-103
.
(r)
(i)
"Drug" means:
(A)
a substance recognized in the official United States Pharmacopoeia, Official
Homeopathic Pharmacopoeia of the United States, or Official National
Formulary, or any supplement to any of them, intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease in humans or
animals;
(B)
a substance that is required by any applicable federal or state law or rule to be
dispensed by prescription only or is restricted to administration by practitioners
only;
(C)
a substance other than food intended to affect the structure or any function of
the body of humans or other animals; and
(D)
substances intended for use as a component of any substance specified in
Subsections
(1)(r)(i)(A)
, (B), and (C).
(ii)
"Drug" does not include dietary supplements.
(iii)
"Drug" includes a food intended for human consumption that intentionally
contains a vaccine or vaccine material as provided in Section
4-5-107
.
(s)
"Drug dependent person" means any individual who unlawfully and habitually uses
any controlled substance to endanger the public morals, health, safety, or welfare, or
who is so dependent upon the use of controlled substances as to have lost the power
of self-control with reference to the individual's dependency.
(t)
(i)
"Food" means:
(A)
any nutrient or substance of plant, mineral, or animal origin other than a drug
as specified in this chapter, and normally ingested by human beings; and
(B)
foods for special dietary uses as exist by reason of a physical, physiological,
pathological, or other condition including the conditions of disease,
convalescence, pregnancy, lactation, allergy, hypersensitivity to food,
underweight, and overweight; uses for supplying a particular dietary need
which exist by reason of age including the ages of infancy and childbirth, and
also uses for supplementing and for fortifying the ordinary or unusual diet with
any vitamin, mineral, or other dietary property for use of a food.
(ii)
Any particular use of a food is a special dietary use regardless of the nutritional
purposes.
(u)
"Immediate precursor" means a substance which the Attorney General of the United
States has found to be, and by regulation designated as being, the principal compound
used or produced primarily for use in the manufacture of a controlled substance, or
which is an immediate chemical intermediary used or likely to be used in the
manufacture of a controlled substance, the control of which is necessary to prevent,
curtail, or limit the manufacture of the controlled substance.
(v)
"Indian" means a member of an Indian tribe.
(w)
"Indian religion" means a religion:
(i)
the origin and interpretation of which is from within a traditional Indian culture or
community; and
(ii)
that is practiced by Indians.
(x)
"Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
community of Indians, including any Alaska Native village, which is legally
recognized as eligible for and is consistent with the special programs, services, and
entitlements provided by the United States to Indians because of their status as
Indians.
(y)
"Manufacture" means the production, preparation, propagation, compounding, or
processing of a controlled substance, either directly or indirectly by extraction from
substances of natural origin, or independently by means of chemical synthesis or by a
combination of extraction and chemical synthesis.
(z)
"Manufacturer" includes any person who packages, repackages, or labels any
container of any controlled substance, except pharmacists who dispense or compound
prescription orders for delivery to the ultimate consumer.
(aa)
(i)
"Marijuana" means all species of the genus cannabis and all parts of the genus,
whether growing or not, including:
(A)
seeds;
(B)
resin extracted from any part of the plant, including the resin extracted from
the mature stalks;
(C)
every compound, manufacture, salt, derivative, mixture, or preparation of the
plant, seeds, or resin;
(D)
any synthetic equivalents of the substances contained in the plant cannabis
sativa or any other species of the genus cannabis which are chemically
indistinguishable and pharmacologically active; and
(E)
any component part or cannabinoid extracted or isolated from the plant,
including extracted or isolated tetrahydrocannabinols.
(ii)
"Marijuana" does not include:
(A)
the mature stalks of the plant;
(B)
fiber produced from the stalks;
(C)
oil or cake made from the seeds of the plant;
(D)
except as provided in Subsection
(1)(aa)(i)
, any other compound,
manufacture, salt, derivative, mixture, or preparation of the mature stalks,
fiber, oil or cake;
(E)
the sterilized seed of the plant which is incapable of germination;
(F)
any compound, mixture, or preparation approved by the federal Food and
Drug Administration under the federal Food, Drug, and Cosmetic Act, 21
U.S.C. Sec. 301 et seq. that is not listed in a schedule of controlled substances
in Section
58-37-4
or in the federal Controlled Substances Act, Title II, P.L.
91-513; or
(G)
transportable industrial hemp concentrate as that term is defined in Section
4-41-102
.
(bb)
"Money" means officially issued coin and currency of the United States or any
foreign country.
(cc)
"Narcotic drug" means any of the following, whether produced directly or indirectly
by extraction from substances of vegetable origin, or independently by means of
chemical synthesis, or by a combination of extraction and chemical synthesis:
(i)
opium, coca leaves, and opiates;
(ii)
a compound, manufacture, salt, derivative, or preparation of opium, coca leaves,
or opiates;
(iii)
opium poppy and poppy straw; or
(iv)
a substance, and any compound, manufacture, salt, derivative, or preparation of
the substance, which is chemically identical with any of the substances referred to
in Subsection
(1)(cc)(i)
, (ii), or (iii), except narcotic drug does not include
decocainized coca leaves or extracts of coca leaves which do not contain cocaine
or ecgonine.
(dd)
"Negotiable instrument" means documents, containing an unconditional promise to
pay a sum of money, which are legally transferable to another party by endorsement
or delivery.
(ee)
"Opiate" means any drug or other substance having an addiction-forming or
addiction-sustaining liability similar to morphine or being capable of conversion into
a drug having addiction-forming or addiction-sustaining liability.
(ff)
"Opium poppy" means the plant of the species papaver somniferum L., except the
seeds of the plant.
(gg)
"Person" means any corporation, association, partnership, trust, other institution or
entity or one or more individuals.
(hh)
"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
(ii)
"Possession" or "use" means the joint or individual ownership, control, occupancy,
holding, retaining, belonging, maintaining, or the application, inhalation, swallowing,
injection, or consumption, as distinguished from distribution, of controlled
substances and includes individual, joint, or group possession or use of controlled
substances. For a person to be a possessor or user of a controlled substance, it is not
required that the person be shown to have individually possessed, used, or controlled
the substance, but it is sufficient if it is shown that the person jointly participated with
one or more persons in the use, possession, or control of any substances with
knowledge that the activity was occurring, or the controlled substance is found in a
place or under circumstances indicating that the person had the ability and the intent
to exercise dominion and control over the controlled substance.
(jj)
"Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
pharmacist, scientific investigator, pharmacy, hospital, or other person licensed,
registered, or otherwise permitted to distribute, dispense, conduct research with
respect to, administer, or use in teaching or chemical analysis a controlled substance
in the course of professional practice or research in this state.
(kk)
"Prescribe" means to issue a prescription:
(i)
orally or in writing; or
(ii)
by telephone, facsimile transmission, computer, or other electronic means of
communication as defined by division rule.
(ll)
"Prescription" means an order issued:
(i)
by a licensed practitioner, in the course of that practitioner's professional practice
or by collaborative pharmacy practice agreement; and
(ii)
for a controlled substance or other prescription drug or device for use by a patient
or an animal.
(mm)
"Production" means the manufacture, planting, cultivation, growing, or harvesting
of a controlled substance.
(nn)
"Securities" means any stocks, bonds, notes, or other evidences of debt or of
property.
(oo)
"State" means the state of Utah.
(pp)
"Total kratom alkaloid composition" means the total amount of all alkaloids derived
from the Mitragyna speciosa plant.
(pp)
(qq)
"Ultimate user" means any person who lawfully possesses a controlled
substance for the person's own use, for the use of a member of the person's
household, or for administration to an animal owned by the person or a member of
the person's household.
(2)
If a term used in this chapter is not defined, the definition and terms of Title 76, Utah
Criminal Code, shall apply.
Section 3. Section
58-37-4
is amended to read:
58-37-4
. Schedules of controlled substances -- Schedules I through V -- Findings
required -- Specific substances included in schedules.
(1)
There are established five schedules of controlled substances known as Schedules I, II,
III, IV, and V which consist of substances listed in this section.
(2)
Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
official name, common or usual name, chemical name, or brand name designated:
(a)
Schedule I:
(i)
Unless specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
salts is possible within the specific chemical designation:
(A)
Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(B)
Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(C)
Acetylmethadol;
(D)
Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
(E)
Allylprodine;
(F)
Alphacetylmethadol, except levo-alphacetylmethadol also known as
levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
(G)
Alphameprodine;
(H)
Alphamethadol;
(I)
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(J)
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
piperidinyl]-N-phenylpropanamide);
(K)
Benzylpiperazine;
(L)
Benzethidine;
(M)
Betacetylmethadol;
(N)
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
piperidinyl]-N-phenylpropanamide);
(O)
Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
(P)
Betameprodine;
(Q)
Betamethadol;
(R)
Betaprodine;
(S)
Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
(T)
Clonitazene;
(U)
Cyclopropyl fentanyl
(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
(V)
Dextromoramide;
(W)
Diampromide;
(X)
Diethylthiambutene;
(Y)
Difenoxin;
(Z)
Dimenoxadol;
(AA)
Dimepheptanol;
(BB)
Dimethylthiambutene;
(CC)
Dioxaphetyl butyrate;
(DD)
Dipipanone;
(EE)
Ethylmethylthiambutene;
(FF)
Etizolam
(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
(GG)
Etonitazene;
(HH)
Etoxeridine;
(II)
Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
furan-2-carboxamide);
(JJ)
Furethidine;
(KK)
Hydroxypethidine;
(LL)
Ketobemidone;
(MM)
Levomoramide;
(NN)
Levophenacylmorphan;
(OO)
Methoxyacetyl fentanyl
(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
(PP)
Morpheridine;
(QQ)
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(RR)
Noracymethadol;
(SS)
Norlevorphanol;
(TT)
Normethadone;
(UU)
Norpipanone;
(VV)
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
propanamide);
(WW)
Para-fluoroisobutyryl fentanyl
(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
(XX)
PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(YY)
Phenadoxone;
(ZZ)
Phenampromide;
(AAA)
Phenibut;
(BBB)
Phenomorphan;
(CCC)
Phenoperidine;
(DDD)
Piritramide;
(EEE)
Proheptazine;
(FFF)
Properidine;
(GGG)
Propiram;
(HHH)
Racemoramide;
(III)
Tetrahydrofuran fentanyl
(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
(JJJ)
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
(KKK)
Tianeptine;
(LLL)
Tilidine;
(MMM)
Trimeperidine;
(NNN)
3-methylfentanyl, including the optical and geometric isomers
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
(OOO)
3-methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(PPP)
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
known as U-47700; and
(QQQ)
4-cyano CUMYL-BUTINACA.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the
following opium derivatives, their salts, isomers, and salts of isomers when the
existence of the salts, isomers, and salts of isomers is possible within the specific
chemical designation:
(A)
Acetorphine;
(B)
Acetyldihydrocodeine;
(C)
Benzylmorphine;
(D)
Codeine methylbromide;
(E)
Codeine-N-Oxide;
(F)
Cyprenorphine;
(G)
Desomorphine;
(H)
Dihydromorphine;
(I)
Drotebanol;
(J)
Etorphine (except hydrochloride salt);
(K)
Heroin;
(L)
Hydromorphinol;
(M)
Methyldesorphine;
(N)
Methylhydromorphine;
(O)
Morphine methylbromide;
(P)
Morphine methylsulfonate;
(Q)
Morphine-N-Oxide;
(R)
Myrophine;
(S)
Nicocodeine;
(T)
Nicomorphine;
(U)
Normorphine;
(V)
Pholcodine; and
(W)
Thebacon.
(iii)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of their salts, isomers, and salts
of isomers when the existence of the salts, isomers, and salts of isomers is possible
within the specific chemical designation; as used in this Subsection
(2)(a)(iii)

only, "isomer" includes the optical, position, and geometric isomers:
(A)
Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
-ET; and AET;
(B)
4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
4-bromo-2,5-dimethoxy-
-methylphenethylamine; 4-bromo-2,5-DMA;
(C)
4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
2C-B, Nexus;
(D)
2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-
-methylphenethylamine; 2,5-DMA;
(E)
2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
(F)
4-methoxyamphetamine, some trade or other names: 4-methoxy-
-methylphenethylamine; paramethoxyamphetamine, PMA;
(G)
5-methoxy-3,4-methylenedioxyamphetamine;
(H)
4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
4-methyl-2,5-dimethoxy-
-methylphenethylamine; "DOM"; and "STP";
(I)
3,4-methylenedioxy amphetamine;
(J)
3,4-methylenedioxymethamphetamine (MDMA);
(K)
3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
MDEA;
(L)
N-hydroxy-3,4-methylenedioxyamphetamine, also known as
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
MDA;
(M)
3,4,5-trimethoxy amphetamine;
(N)
Bufotenine, some trade and other names: 3-(
-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
(O)
Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
(P)
Dimethyltryptamine, some trade or other names: DMT;
(Q)
Ibogaine, some trade and other names: 7-Ethyl-6,6
,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
azepino [5,4-b] indole; Tabernanthe iboga;
(R)
Lysergic acid diethylamide;
(S)
Marijuana;
(T)
Mescaline;
(U)
Parahexyl, some trade or other names:
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
Synhexyl;
(V)
Peyote, meaning all parts of the plant presently classified botanically as
Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any
extract from any part of such plant, and every compound, manufacture, salts,
derivative, mixture, or preparation of such plant, its seeds or extracts
(Interprets 21 USC 812(c), Schedule I(c) (12));
(W)
N-ethyl-3-piperidyl benzilate;
(X)
N-methyl-3-piperidyl benzilate;
(Y)
Psilocybin;
(Z)
Psilocyn;
(AA)
Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
(cannabis plant), except for marijuana as defined in Subsection
58-37-2
(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
substances, derivatives, and their isomers with similar chemical structure and
pharmacological activity to those substances contained in the plant, such as the
following:
1 cis or trans tetrahydrocannabinol, and their optical isomers
6 cis or
trans tetrahydrocannabinol, and their optical isomers
3,4 cis or trans
tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
substances is not internationally standardized, compounds of these structures,
regardless of numerical designation of atomic positions covered;
(BB)
Ethylamine analog of phencyclidine, some trade or other names:
N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
(CC)
Pyrrolidine analog of phencyclidine, some trade or other names:
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
(DD)
Thiophene analog of phencyclidine, some trade or other names:
1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
TPCP, TCP; and
(EE)
1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
(iv)
Unless specifically excepted or unless listed in another schedule, any material
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including its
salts, isomers, and salts of isomers when the existence of the salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(A)
Mecloqualone; and
(B)
Methaqualone.
(v)
Any material, compound, mixture, or preparation containing any quantity of the
following substances having a stimulant effect on the central nervous system,
including their salts, isomers, and salts of isomers:
(A)
Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
or 4,5-dihydro-5-phenyl-2-oxazolamine;
(B)
Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
(C)
Fenethylline;
(D)
Methcathinone, some other names: 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone;
N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,
its salts, optical isomers, and salts of optical isomers;
(E)
(
)cis-4-methylaminorex ((
)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
(F)
N-ethylamphetamine; and
(G)
N,N-dimethylamphetamine, also known as
N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
(vi)
Any material, compound, mixture, or preparation which contains any quantity of
the following substances, including their optical isomers, salts, and salts of
isomers, subject to temporary emergency scheduling:
(A)
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
(B)
N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
(vii)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of gamma
hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
salts of isomers.
(viii)
Unless specifically excepted or unless listed in another schedule, the following
substances commonly found in Mitragyna speciosa, including synthetic versions,
isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the
existence of the isomers, esters, ethers, and salts is possible within the specific
chemical designation:
(A)
7-hydroxymitragynine (methyl
(E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-
1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate), that is
concentrated at a level greater than .4% of the total kratom alkaloid
composition of any substance or product; and
(B)
Mitragynine pseudoindoxyl (methyl
(E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-
hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate).
(b)
Schedule II:
(i)
Unless specifically excepted or unless listed in another schedule, any of the
following substances whether produced directly or indirectly by extraction from
substances of vegetable origin, or independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:
(A)
Opium and opiate, and any salt, compound, derivative, or preparation of
opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene,
naloxone, and naltrexone, and their respective salts, but including:
(I)
Raw opium;
(II)
Opium extracts;
(III)
Opium fluid;
(IV)
Powdered opium;
(V)
Granulated opium;
(VI)
Tincture of opium;
(VII)
Codeine;
(VIII)
Ethylmorphine;
(IX)
Etorphine hydrochloride;
(X)
Hydrocodone;
(XI)
Hydromorphone;
(XII)
Metopon;
(XIII)
Morphine;
(XIV)
Oxycodone;
(XV)
Oxymorphone; and
(XVI)
Thebaine;
(B)
Any salt, compound, derivative, or preparation which is chemically equivalent
or identical with any of the substances referred to in Subsection
(2)(b)(i)(A)
,
except that these substances may not include the isoquinoline alkaloids of
opium;
(C)
Opium poppy and poppy straw;
(D)
Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
and any salt, compound, derivative, or preparation which is chemically
equivalent or identical with any of these substances, and includes cocaine and
ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
whether derived from the coca plant or synthetically produced, except the
substances may not include decocainized coca leaves or extraction of coca
leaves, which extractions do not contain cocaine or ecgonine; and
(E)
Concentrate of poppy straw, which means the crude extract of poppy straw in
either liquid, solid, or powder form which contains the phenanthrene alkaloids
of the opium poppy.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
salts is possible within the specific chemical designation, except dextrorphan and
levopropoxyphene:
(A)
Alfentanil;
(B)
Alphaprodine;
(C)
Anileridine;
(D)
Bezitramide;
(E)
Bulk dextropropoxyphene (nondosage forms);
(F)
Carfentanil;
(G)
Dihydrocodeine;
(H)
Diphenoxylate;
(I)
Fentanyl;
(J)
Isomethadone;
(K)
Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
levomethadyl acetate, or LAAM;
(L)
Levomethorphan;
(M)
Levorphanol;
(N)
Metazocine;
(O)
Methadone;
(P)
Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(Q)
Moramide-Intermediate, 2-methyl-3-morpholino-1,
1-diphenylpropane-carboxylic acid;
(R)
Pethidine (meperidine);
(S)
Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(T)
Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(U)
Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(V)
Phenazocine;
(W)
Piminodine;
(X)
Racemethorphan;
(Y)
Racemorphan;
(Z)
Remifentanil; and
(AA)
Sufentanil.
(iii)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system:
(A)
Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(B)
Methamphetamine, its salts, isomers, and salts of its isomers;
(C)
Phenmetrazine and its salts; and
(D)
Methylphenidate.
(iv)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including its
salts, isomers, and salts of isomers when the existence of the salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(A)
Amobarbital;
(B)
Glutethimide;
(C)
Pentobarbital;
(D)
Phencyclidine;
(E)
Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
1-piperidinocyclohexanecarbonitrile (PCC); and
(F)
Secobarbital.
(v)
(A)
Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of
Phenylacetone.
(B)
Some of these substances may be known by trade or other names:
phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
(vi)
Nabilone, another name for nabilone: (
)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
(vii)
A drug product or preparation that contains any component of marijuana,
including tetrahydrocannabinol, and is approved by the United States Food and
Drug Administration and scheduled by the Drug Enforcement Administration in
Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
(c)
Schedule III:
(i)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system, including its
salts, isomers whether optical, position, or geometric, and salts of the isomers
when the existence of the salts, isomers, and salts of isomers is possible within the
specific chemical designation:
(A)
Those compounds, mixtures, or preparations in dosage unit form containing
any stimulant substances listed in Schedule II, which compounds, mixtures, or
preparations were listed on August 25, 1971, as excepted compounds under
Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
drug of the quantitive composition shown in that list for those drugs or which
is the same except that it contains a lesser quantity of controlled substances;
(B)
Benzphetamine;
(C)
Chlorphentermine;
(D)
Clortermine; and
(E)
Phendimetrazine.
(ii)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system:
(A)
Any compound, mixture, or preparation containing amobarbital, secobarbital,
pentobarbital, or any salt of any of them, and one or more other active
medicinal ingredients which are not listed in any schedule;
(B)
Any suppository dosage form containing amobarbital, secobarbital, or
pentobarbital, or any salt of any of these drugs which is approved by the
United
States
Food and Drug Administration for marketing only as a suppository;
(C)
Any substance which contains any quantity of a derivative of barbituric acid
or any salt of any of them;
(D)
Chlorhexadol;
(E)
Buprenorphine;
(F)
Any drug product containing gamma hydroxybutyric acid, including its salts,
isomers, and salts of isomers, for which an application is approved under the
federal Food, Drug, and Cosmetic Act, Section 505;
(G)
Ketamine, its salts, isomers, and salts of isomers, some other names for
ketamine:
-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
(H)
Lysergic acid;
(I)
Lysergic acid amide;
(J)
Methyprylon;
(K)
Sulfondiethylmethane;
(L)
Sulfonethylmethane;
(M)
Sulfonmethane; and
(N)
Tiletamine and zolazepam or any of their salts, some trade or other names for
a tiletamine-zolazepam combination product: Telazol, some trade or other
names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
or other names for zolazepam:
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
[1,4]-diazepin-7(1H)-one, flupyrazapon.
(iii)
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
a U.S. Food and Drug Administration approved drug product, some other names
for dronabinol:
(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
or (-)-delta-9-(trans)-tetrahydrocannabinol.
(iv)
Nalorphine.
(v)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation containing limited quantities of any of the
following narcotic drugs, or their salts calculated as the free anhydrous base or
alkaloid:
(A)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
alkaloid of opium;
(B)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active non-narcotic ingredients in
recognized therapeutic amounts;
(C)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
an isoquinoline alkaloid of opium;
(D)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
more than 15 milligrams per dosage unit, with one or more active, non-narcotic
ingredients in recognized therapeutic amounts;
(E)
Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
than 90 milligrams per dosage unit, with one or more active non-narcotic
ingredients in recognized therapeutic amounts;
(F)
Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
than 15 milligrams per dosage unit, with one or more active, non-narcotic
ingredients in recognized therapeutic amounts;
(G)
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
or not more than 25 milligrams per dosage unit, with one or more active,
non-narcotic ingredients in recognized therapeutic amounts; and
(H)
Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
with one or more active, non-narcotic ingredients in recognized therapeutic
amounts.
(vi)
Unless specifically excepted or unless listed in another schedule, anabolic
steroids including any of the following or any isomer, ester, salt, or derivative of
the following that promotes muscle growth:
(A)
Boldenone;
(B)
Chlorotestosterone (4-chlortestosterone);
(C)
Clostebol;
(D)
Dehydrochlormethyltestosterone;
(E)
Dihydrotestosterone (4-dihydrotestosterone);
(F)
Drostanolone;
(G)
Ethylestrenol;
(H)
Fluoxymesterone;
(I)
Formebulone (formebolone);
(J)
Mesterolone;
(K)
Methandienone;
(L)
Methandranone;
(M)
Methandriol;
(N)
Methandrostenolone;
(O)
Methenolone;
(P)
Methyltestosterone;
(Q)
Mibolerone;
(R)
Nandrolone;
(S)
Norethandrolone;
(T)
Oxandrolone;
(U)
Oxymesterone;
(V)
Oxymetholone;
(W)
Stanolone;
(X)
Stanozolol;
(Y)
Testolactone;
(Z)
Testosterone; and
(AA)
Trenbolone.
(vii)
Anabolic steroids expressly intended for administration through implants to
cattle or other nonhuman species, and approved by the Secretary of Health and
Human Services for use, may not be classified as a controlled substance.
(viii)
A drug product or preparation that contains any component of marijuana,
including tetrahydrocannabinol, and is approved by the United States Food and
Drug Administration and scheduled by the Drug Enforcement Administration in
Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
(ix)
Nabiximols.
(d)
Schedule IV:
(i)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation containing not more than 1 milligram of
difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
any salts of any of them.
(ii)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances, including its salts, isomers, and salts of isomers when the existence of
the salts, isomers, and salts of isomers is possible within the specific chemical
designation:
(A)
Alprazolam;
(B)
Barbital;
(C)
Bromazepam;
(D)
Butorphanol;
(E)
Camazepam;
(F)
Carisoprodol;
(G)
Chloral betaine;
(H)
Chloral hydrate;
(I)
Chlordiazepoxide;
(J)
Clobazam;
(K)
Clonazepam;
(L)
Clorazepate;
(M)
Clotiazepam;
(N)
Cloxazolam;
(O)
Delorazepam;
(P)
Diazepam;
(Q)
Dichloralphenazone;
(R)
Estazolam;
(S)
Ethchlorvynol;
(T)
Ethinamate;
(U)
Ethyl loflazepate;
(V)
Fludiazepam;
(W)
Flunitrazepam;
(X)
Flurazepam;
(Y)
Halazepam;
(Z)
Haloxazolam;
(AA)
Ketazolam;
(BB)
Loprazolam;
(CC)
Lorazepam;
(DD)
Lormetazepam;
(EE)
Mebutamate;
(FF)
Medazepam;
(GG)
Meprobamate;
(HH)
Methohexital;
(II)
Methylphenobarbital (mephobarbital);
(JJ)
Midazolam;
(KK)
Nimetazepam;
(LL)
Nitrazepam;
(MM)
Nordiazepam;
(NN)
Oxazepam;
(OO)
Oxazolam;
(PP)
Paraldehyde;
(QQ)
Pentazocine;
(RR)
Petrichloral;
(SS)
Phenobarbital;
(TT)
Pinazepam;
(UU)
Prazepam;
(VV)
Quazepam;
(WW)
Temazepam;
(XX)
Tetrazepam;
(YY)
Tramadol;
(ZZ)
Triazolam;
(AAA)
Zaleplon; and
(BBB)
Zolpidem.
(iii)
Any material, compound, mixture, or preparation of fenfluramine which contains
any quantity of the following substances, including its salts, isomers whether
optical, position, or geometric, and salts of the isomers when the existence of the
salts, isomers, and salts of isomers is possible.
(iv)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system, including its
salts, isomers whether optical, position, or geometric isomers, and salts of the
isomers when the existence of the salts, isomers, and salts of isomers is possible
within the specific chemical designation:
(A)
Cathine ((+)-norpseudoephedrine);
(B)
Diethylpropion;
(C)
Fencamfamine;
(D)
Fenproprex;
(E)
Mazindol;
(F)
Mefenorex;
(G)
Modafinil;
(H)
Pemoline, including organometallic complexes and chelates thereof;
(I)
Phentermine;
(J)
Pipradrol;
(K)
Sibutramine; and
(L)
SPA ((-)-1-dimethylamino-1,2-diphenylethane).
(v)
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
(vi)
A drug product or preparation that contains any component of marijuana and is
approved by the United States Food and Drug Administration and scheduled by
the Drug Enforcement Administration in Schedule IV of the federal Controlled
Substances Act, Title II, P.L. 91-513.
(e)
Schedule V:
(i)
Any compound, mixture, or preparation containing any of the following limited
quantities of narcotic drugs, or their salts calculated as the free anhydrous base or
alkaloid, which includes one or more non-narcotic active medicinal ingredients in
sufficient proportion to confer upon the compound, mixture, or preparation
valuable medicinal qualities other than those possessed by the narcotic drug alone:
(A)
not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(B)
not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
grams;
(C)
not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
grams;
(D)
not more than 2.5 milligrams of diphenoxylate and not less than 25
micrograms of atropine sulfate per dosage unit;
(E)
not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(F)
not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit; and
(G)
unless specifically exempted or excluded or unless listed in another schedule,
any material, compound, mixture, or preparation which contains Pyrovalerone
having a stimulant effect on the central nervous system, including its salts,
isomers, and salts of isomers.
(ii)
A drug product or preparation that contains any component of marijuana,
including cannabidiol, and is approved by the United States Food and Drug
Administration and scheduled by the Drug Enforcement Administration in
Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
(iii)
Gabapentin.
Section 4.
Effective Date.
This bill takes effect:
(1)
except as provided in Subsection (2),
May 6, 2026
; or
(2)
if approved by two-thirds of all members elected to each house:
(a)
upon approval by the governor;
(b)
without the governor's signature, the day following the constitutional time limit of
Utah Constitution, Article VII, Section 8; or
(c)
in the case of a veto, the date of veto override.
12-23-25 11:17 AM